Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally

Menopause

Volumn 16, Issue 4, 2009, Pages 719-727

  Bachmann, Gloria ^a   Bouchard, Céline ^b   Hoppe, Diana ^c   Ranganath, Radhika ^d   Altomare, Corrado ^d   Vieweg, Alberta ^d   Graepel, Jay ^d   Helzner, Eileen ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Clinique RSF Inc   (Canada)

^c Pacific Coast Women's Health   (United States)

^d Wyeth Research Chemical Development   (Canada)

Author keywords

Atrophic vaginitis; Conjugated estrogens; Endometrial hyperplasia; Postmenopausal; Premarin Vaginal Cream; Vaginal cream

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; ATROPHIC VAGINITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HEADACHE; HUMAN; INFECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OPEN STUDY; PH MEASUREMENT; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VAGINA ATROPHY; VAGINA BLEEDING; VAGINITIS;

ADMINISTRATION, INTRAVAGINAL; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; ENDOMETRIAL HYPERPLASIA; ENDOMETRIUM; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINITIS;

EID: 68449084537     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a48c4e     Document Type: Article

References (21)

1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
2. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008;15:661-666.
3. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231.
4. Ford K, Sowers M, Crutchfield M, Wilson A, Jannausch M. A longitudinal study of the predictors of prevalence and severity of symptoms commonly associated with menopause. Menopause 2005;12:308-317.
5. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000;79:293-297.
6. Parsons A, Merritt D, Rosen A, Heath H III, Siddhanti S, Plouffe L Jr. Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol 2003;101:346-352.
7. American College of Obstetricians and Gynecologists Task Force on Hormone Therapy. Sexual dysfunction. Obstet Gynecol 2004;104:85S-91S.
8. Mandel FP, Geola FL, Meldrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1983;57:133-139.
9. Raymundo N, Yu-cheng B, Zi-yan H, et al. Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. Climacteric 2004;7:312-318.
10. Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can 2004;26:503-515.
11. Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guidelines. The detection and management of vaginal atrophy. Number 145, May 2004. Int J Gynaecol Obstet 2005;88:222-228.
12. Freedman M. Vaginal pH, estrogen and genital atrophy. Menopause Manag 2008;17:9-13.
13. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885-889.
14. North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: March 2007 position statement of the North American Menopause Society. Menopause 2007;14:1-17.
15. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
16. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001;184:255-263.
17. Balfour JA, Heel RC. Transdermal estradiol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of menopausal complaints. Drugs 1990;40:561-582.
18. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas 1990;12:171-197.
19. Minkin MJ. Considerations in the choice of oral vs. transdermal hormone therapy: a review. J Reprod Med 2004;49:311-320.
20. Crandall C. Vaginal estrogen preparations: a review of safety and efficacy for vaginal atrophy. J Womens Health (Larchmt) 2002;11:857-877.
21. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.